← Back to Search

CAR T-cell Therapy

CTX110 for B-Cell Cancers

Phase 1 & 2
Waitlist Available
Research Sponsored by CRISPR Therapeutics AG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
For NHL patients: Age ≥18 years.
For B cell ALL patients: age ≥18 years to ≤70 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from ctx110 infusion up to 60 months post-infusion
Awards & highlights

Study Summary

This trial is testing a new drug, CTX110, for safety and effectiveness in treating people with B-cell malignancies that have come back or are not responding to treatment.

Who is the study for?
This trial is for adults with B-cell malignancies like non-Hodgkin's lymphoma or acute lymphoblastic leukemia that didn't respond to at least two prior treatments. Participants must be in good physical condition, have well-functioning major organs, and not be pregnant or breastfeeding. They should agree to use contraception and join a follow-up study.Check my eligibility
What is being tested?
The CARBON trial is testing the safety and effectiveness of CTX110, a new therapy for people with certain blood cancers that have come back or haven't responded to treatment. It's an early-phase study where everyone gets the same experimental treatment.See study design
What are the potential side effects?
While specific side effects of CTX110 are not listed here, similar therapies can cause immune reactions, infections due to lowered immunity, fatigue, fever, and potential organ damage among other symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older with non-Hodgkin lymphoma.
Select...
I am between 18 and 70 years old with B cell ALL.
Select...
I am fully active or can carry out light work.
Select...
I am at least 18 years old.
Select...
My non-Hodgkin lymphoma or B cell ALL has not improved after at least 2 treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from ctx110 infusion up to 60 months post-infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and from ctx110 infusion up to 60 months post-infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase 1 Part A (Dose Escalation), for all cohorts: Incidence of adverse events, defined as dose-limiting toxicities
Phase 1 Part B (Cohort Expansion) and Phase 2: Objective response rate
Secondary outcome measures
Duration of Clinical Benefit (DOCB)
Duration of Response
Objective Response Rate (for B cell ALL)
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: CTX110Experimental Treatment1 Intervention
Administered by IV infusion following lymphodepleting chemotherapy.

Find a Location

Who is running the clinical trial?

CRISPR Therapeutics AGLead Sponsor
8 Previous Clinical Trials
665 Total Patients Enrolled
Sarah Cohen, MDStudy DirectorCRISPR Therapeutics
2 Previous Clinical Trials
146 Total Patients Enrolled
Ewelina Morawa, MDStudy DirectorCRISPR Therapeutics
1 Previous Clinical Trials
26 Total Patients Enrolled

Media Library

CTX110 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04035434 — Phase 1 & 2
B-Cell Cancers Research Study Groups: CTX110
B-Cell Cancers Clinical Trial 2023: CTX110 Highlights & Side Effects. Trial Name: NCT04035434 — Phase 1 & 2
CTX110 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04035434 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What adverse effects has CTX110 been associated with?

"Due to the limited clinical data supporting both efficacy and safety, CTX110 received a score of 1 on our assessment scale."

Answered by AI

How prevalent is this clinical trial's implementation in the city?

"Currently, 18 medical centres across the United States are hosting this clinical trial. Locations span from Jacksonville to Saint Louis and Philadelphia with other sites in between. To reduce travel burden, it is best for patients to seek a nearby clinic if they plan on enrolling."

Answered by AI

How many participants have registered for the research project?

"This clinical trial necessitates the participation of 143 qualified patients, who can elect to take part at either Mayo Clinic in Jacksonville, FL or Washington University in Saint Louis, MO."

Answered by AI

Are there any open slots for participants in this clinical trial?

"Based on the information posted to clinicaltrials.gov, this research is presently recruiting participants; the trial was first published in July 2019 and its details were last modified in May 2022."

Answered by AI

Who else is applying?

What state do they live in?
Pennsylvania
How old are they?
65+
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
2019. "A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04035434.
~71 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top